Navigating the Long Haul to Normalcy

Create a vendor selection project
Click to express your interest in this report
Indication of coverage against your requirements
A subscription is required to activate this feature. Contact us for more info.
Celent have reviewed this profile and believe it to be accurate.
We are waiting for the vendor to publish their solution profile. Contact us or request the RFX.
Projects allow you to export Registered Vendor details and survey responses for analysis outside of Marsh CND. Please refer to the Marsh CND User Guide for detailed instructions.
Download Registered Vendor Survey responses as PDF
Contact vendor directly with specific questions (ie. pricing, capacity, etc)
23 November 2020

Oliver Wyman


Recent Oliver Wyman analysis shows that the fourth quarter of 2021 is likely the earliest we can get close to “back to normal” in the United States, even with the promising vaccine efficacy news. Given this timing, companies must consider if what has been working for the past seven months can be sustained for the next 12 to 15 months, and what they may need to adjust.

The key to “getting back to normal” is cumulative immunity, which has several dimensions that need to be considered: the percentage of the population that has already been infected and has protective immunity, and the percentage of the population that is either naturally immune to infection or has been effectively vaccinated. We need enough cumulative immunity present in the population to stop the virus from spreading.

In The Long Haul to Normalcy, which leverages our Pandemic Navigator and team of infectious disease experts, we provide four possible scenarios on when the appropriate threshold immunity can be achieved and share the key levers that impact timing and the likelihood of success – both hindrances and accelerants. The research also offers business leaders three “no regret” moves to aid their planning and response efforts.

Report files